Arcutis Biotherapeutics: Pay

Arcutis Biotherapeutics paid its 6 named executives $19.3M in total in FY2025 (Dec). CEO Todd Franklin Watanabe was paid $7.2M of that.

Pay$100 in the stock at the end of FY21 → $140
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Todd Franklin WatanabePresident and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
L. Todd EdwardsChief Commercial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
3 years
Patrick E. Burnett
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
3 years
Masaru Matsuda, J.D.Chief Legal Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
David TopperFormer Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Latha VairavanChief Financial Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $8.1M. The CEO of Arcutis Biotherapeutics was paid $7.2M, 11% below the median.

  1. 1Protagonist Therapeutics
  2. 2Mirum Pharmaceuticals
  3. 3Travere Therapeutics
  4. 4Ardelyx
  5. 5Arcutis Biotherapeutics
  6. 6Tarsus Pharmaceuticals
  7. 7Agios Pharmaceuticals
  8. 8AnaptysBioNot disclosed
  9. 9Biocryst PharmaceuticalsNot disclosed
  10. 10Dynavax TechnologiesNot disclosed
  11. 11EvolusNot disclosed
  12. 12MannkindNot disclosed
  13. 13Ocular TherapeuticsNot disclosed
  14. 14Phathom PharmaceuticalsNot disclosed
  15. 15Sage TherapeuticsNot disclosed
  16. 16Vanda PharmaceuticalsNot disclosed
  17. 17VericelNot disclosed
  18. 18Y-mAbs TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.